Company intelligence / Profile preview
Nippon Shinyaku
Minami-ku, Kyoto, Kyoto Prefecture, Japannippon-shinyaku.co.jp ↗
- Ownership
- Public · 4516
- Employees
- ~2243
- Development stage
- Other
01
Overview
Global pharmaceutical company with commercialized products including Uptravi® (PAH), Defitelio® (SOS/VOD), and Viltepso® (DMD). Actively developing nucleic acid therapies and expanding global presence.
- Therapeutic areas
- GastroenterologyCardiovascularMen's HealthOncologyRare Diseases
- Modalities
- Small moleculesNucleic acid drugs(Developing gene therapy)
- Industry
- Biotech
02
Drug pipeline
24 assets23 more assets in the full pipeline.
03
Partnerships
- Johnson & Johnson (Uptravi global commercialization)[6]
04
Financials
- Market cap
- $1.4B
- Total revenue
- $1.1B
- Enterprise value
- $979.7M
Beyond the preview
Go deeper on Nippon Shinyaku.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nippon Shinyaku.